Hodgkin's Disease, Neoplasms, Non-Hodgkin's Lymphoma
Conditions
Keywords
taxanes, multidrug resistance, mutant tubulin binding, Hodgkin's or Non-Hodgkin's Lymphoma
Brief summary
Tapestry Pharmaceuticals, Inc. has developed a novel taxane analog, TPI 287. TPI 287 is synthetically manufactured from naturally occurring taxanes extracted from yew starting material. The synthesis involves modification to the taxane side chain to overcome multidrug resistance and to achieve mutant tubulin binding. This study will be a multi-center, dose escalation, sequential group, Phase 1 study evaluating the intravenous administration of TPI 287 on an every 21 day cycle.
Detailed description
The primary objective of this study is to determine the maximum tolerated dose of TPI 287 administered every 21 days for Phase II clinical trials.
Interventions
Sponsors
Cortice Biosciences, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
Patients must be/have: * Histological evidence of malignancy * Advanced solid tumors that have recurred or progressed following standard therapy * Failed one prior therapy or have no standard therapy available * Ambulatory with ECOG of 0-1 and estimated life expectancy of \> 3 months * If female, negative pregnancy test * If of childbearing years, agree to use birth control * If patient with prior radiation therapy for brain metastases, on steroids, must have been stable for 1 month
Exclusion criteria
Patients will be excluded if they are or have had: * Prior radiation within 4 weeks * Active medical condition or organ disease which may compromise safety or interfere with the study * Clinically significant cardiac co-morbidities or pulmonary impairment * Concomitant therapy needs * Treated with any investigational drugs within 30 days * Tumors involve major artery or vein * Prior or concurrent central nervous system (CNS) disease * Less than 4 weeks since major surgery * Known to be positive for HIV, hepatitis B or C * Concurrent use of aspirin * Use of thrombolytic agents * Uncontrolled hypertension * Grade II-IV peripheral vascular disease * Pregnant or lactating * Prior allergic history to compounds of similar chemical composition * Inpatients * Grade II-IV peripheral neuropathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the maximum tolerated dose of TPI 287 administered every 21 days | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine the safety of TPI 287 | — |
| To determine the antitumor activity of TPI 287 | — |
| To determine the pharmacokinetic profile of TPI 287 | — |
Countries
United States
Outcome results
None listed